We are international
Donate
TEXT SIZE   


Myeloma Minute
July 7, 2016
07.07.16
July 7, 2016
Share the Minute Facebook Tweet!
Clinical Trials
Donate to the IMF
   

 
This week's question: Can you help make sense of statistics?


Multiple Myeloma Bone Study

New ARROW Clinical Trials: Learn How To Participate

New Selinexor STORM Clinical Trials: Learn How To Participate

New Ixazomib Clinical Trials: Learn How To Participate

Join the conversation about myeloma on the Smart Patients Message Board

Upcoming Events

 

July 7, 2016
Free Teleconference: Register Here

Myeloma Updates 2016: ASCO/EHA/IMWG

 

July 10, 2016
3rd Annual Red House Carnival

Somerville, Massachusetts

July 22, 2016
3rd Annual Chek Fest Golf Tournament

Allendale, MI

August 19-20, 2016
Patient & Family Seminar

Los Angeles, California

August 21, 2016
Community Picnic Day

Los Angeles - Griffith Park

 

 

 

 

 

    

x

Big Data Sharing Is Fundamental to Our Research Success

Vice President Joe Biden’s recent National Cancer Moonshot Summit concluded with the announcement of a “shared data initiative.” “The IMF’s International Myeloma Working Group (IMWG) has been gathering and sharing data from all major myeloma institutions globally for more than a decade,” writes IMF Chairman Dr. Brian Durie in his blog this week.  “And our Black Swan Research Initiative® is actively sharing data on our path to find the cure.” To read Dr. Durie’s blog, click HERE.

x

European Commission Approves Extended Indication for Kyprolis for the Treatment of Relapsed Multiple Myeloma


 

The Committee for Medicinal Products for Human Use (CHMP)—a division of the European Medicines Agency—recommended a change to the terms of the marketing authorization for Kyprolis® (carfilzomib) for the treatment of relapsed multiple myeloma. As of July 3, 2016, CHMP approved Kyprolis in combination with dexamethasone alone to treat adult patients who have received at least one prior therapy. To learn more, click HERE.

x

Now Available: New IMF Brochure "Understanding" Publications on Darzalex and Farydak


 

The IMF’s Understanding Darzalex® (daratumumab) injection offers insight into this laboratory-made monoclonal antibody that targets a specific single protein on the surface of myeloma cells. Darzalex is approved for patients with myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory drug, or who are double-refractory to a proteasome inhibitor and an immunomodulatory drug.  The IMF’s Understanding Farydak® (panobinostat) capsules  brochure focuses on the first histone deacetylase (HDAC) inhibitor approved to treat myeloma. Farydak is approved for use in combination with Velcade® (bortezomib) and the steroid dexamethasone for the treatment of patients with relapsed/refractory myeloma who have received at least two prior regimens. The IMF also has tip cards on both drugs. For a complete list of our publications, click HERE.

x

The IMF Recognizes and Salutes Our Members in the Latest Issue of Making Miracles


 

In Making Miracles, the IMF spotlights and recognizes the many people who lend their enthusiasm, passion, time, and energy to help us empower and support the myeloma community. The latest issue features stories about Aleta George’s personal challenge to swim 30 miles in 30 days, two families coming together to organize “A Race to Beat Myeloma,” and more! To download your copy, click HERE.

x  

IMF Co-Hosts Another Successful Patient & Family Seminar in Vienna




  

The Patient & Family Seminar in Vienna on June 25, 2016, co-hosted by the IMF and Elfi Jirsa, President of Multiples Myelom and Lymphomhilfe Österreich, was a great success. The seminar organizers were especially pleased to welcome Andy Sninsky, a US myeloma patient who has been traveling across Europe by bike to raise awareness about myeloma. As a multiple myeloma patient whose disease is now in complete response, Andy inspired many patients in attendance. Also appreciated was Anita Hörburger and Dr. Iris Herscovici’s discussion of a quality of life tool that they created. Attendees were updated on the advances in myeloma treatment and management from presentations by Drs. Jens Hillengass (Heidelberg Unviersity) and Heinz Ludwig (Wilhelminen Hospital Hospital), and by psychotherapist Marc Sattler.

x

Shop for Major Discounts on Amazon Prime Day and Support the IMF


  

Amazon's second annual Prime Day is on Tuesday, July 12th  at 12 AM PT/ 3 AM ET.  The online retailer will offer Prime members new deals as frequently as every five minutes. This exciting sale will include more than100,000 deals spanning nearly all departments and categories. By shopping at this link, you’ll get discounts on Amazon’s warehouse of items while donating to the IMF at the same time! For every purchase, Amazon will donate 0.5% of the price of your eligible AmazonSmile purchases to the International Myeloma Foundation!


Join Our Mailing List

 
                                                                We Would Like to Thank Our Sponsors:
 
Takeda Oncology, Celgene, Amgen, and Bristol-Myers Squibb
 
12650 Riverside Drive, Suite 206 | North Hollywood, CA 91607-3421
IMF InfoLine: 800-452-2873 or 818-487-7455
Privacy Policy | Unsubscribe
www.myeloma.org

.

 


 related articles